Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles M Perou

Showing results (401-410 of 447) with videos related to

Pageof 45
Sort By:
JAMA Oncology|January 18, 2024
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical TrialCynthia X Ma, Vera J Suman, Souzan Sanati, et al.
Molecular & Cellular Proteomics : MCP|May 9, 2015
Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast CancerChristian D Young, Lisa J Zimmerman, Daisuke Hoshino, et al.
Cell Reports. Medicine|June 6, 2025
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkersEric J Jaehnig, Aranzazu Fernandez-Martinez, Tanmayi D Vashist, et al.
Science (New York, N.Y.)|July 21, 2018
VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinomaJing Zhang, Tao Wu, Jeremy Simon, et al.
NPJ Breast Cancer|April 25, 2025
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumabRodrigo Sánchez-Bayona, Olga Martínez-Sáez, Denys Romero-Romero, et al.
JCO Precision Oncology|July 9, 2025
Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL TrialYash N Agrawal, Aranzazu Fernández-Martínez, Miguel Gil-Gil, et al.
Cell|October 10, 2015
Comprehensive Molecular Portraits of Invasive Lobular Breast CancerGiovanni Ciriello, Michael L Gatza, Andrew H Beck, et al.
The Journal of Pathology|November 19, 2016
The molecular basis of breast cancer pathological phenotypesYujing J Heng, Susan C Lester, Gary Mk Tse, et al.
Nature Communications|January 29, 2020
Microscaled proteogenomic methods for precision oncologyShankha Satpathy, Eric J Jaehnig, Karsten Krug, et al.
Nature Cancer|February 12, 2024
Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilitiesYi-Zhou Jiang, Ding Ma, Xi Jin, et al.
Pageof 45

Showing results (401-410 of 447) with videos related to

Sort By:
Pageof 45
JAMA Oncology|January 18, 2024
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical TrialCynthia X Ma, Vera J Suman, Souzan Sanati, et al.
Molecular & Cellular Proteomics : MCP|May 9, 2015
Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast CancerChristian D Young, Lisa J Zimmerman, Daisuke Hoshino, et al.
Cell Reports. Medicine|June 6, 2025
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkersEric J Jaehnig, Aranzazu Fernandez-Martinez, Tanmayi D Vashist, et al.
Science (New York, N.Y.)|July 21, 2018
VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinomaJing Zhang, Tao Wu, Jeremy Simon, et al.
NPJ Breast Cancer|April 25, 2025
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumabRodrigo Sánchez-Bayona, Olga Martínez-Sáez, Denys Romero-Romero, et al.
JCO Precision Oncology|July 9, 2025
Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL TrialYash N Agrawal, Aranzazu Fernández-Martínez, Miguel Gil-Gil, et al.
Cell|October 10, 2015
Comprehensive Molecular Portraits of Invasive Lobular Breast CancerGiovanni Ciriello, Michael L Gatza, Andrew H Beck, et al.
The Journal of Pathology|November 19, 2016
The molecular basis of breast cancer pathological phenotypesYujing J Heng, Susan C Lester, Gary Mk Tse, et al.
Nature Communications|January 29, 2020
Microscaled proteogenomic methods for precision oncologyShankha Satpathy, Eric J Jaehnig, Karsten Krug, et al.
Nature Cancer|February 12, 2024
Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilitiesYi-Zhou Jiang, Ding Ma, Xi Jin, et al.
Pageof 45